/

Empresas

As

No verificado

AstraZeneca

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

116 Comunicados de prensa

Ver todos los comunicados de prensa

27/07/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Fuente

Editor

1.00

0

27/07/2026

Web y redes sociales

Mercado laboral

Telefonía

Mercado de valores

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

AstraZeneca results: H1 and Q2 2026

Fuente

Editor

1.00

0

24/06/2026

Mercado laboral

Industria

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

Fuente

Editor

1.00

0

12/06/2026

Higiene alimentaria

Tercera edad

Medicina - Varios

Biotecnología

Salud

Ir de compras

Farmacéutica

Oncología

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Fuente

Editor

1.00

0

02/06/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

Fuente

Editor

1.00

0

01/06/2026

Ciencia

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

Eventos

Industria

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Fuente

Editor

1.00

0

29/05/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

Fuente

Editor

1.00

0

22/05/2026

Industria

Ciencia

Medicina - Varios

Higiene alimentaria

Biotecnología

Salud

Farmacéutica

Oncología

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

Fuente

Editor

1.00

0

22/05/2026

Ciencia

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

Eventos

Industria

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

Fuente

Editor

1.00

0

18/05/2026

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0